We announced the completion of our Solid Form Services expansion at our Bend (US) site.
We also reported strong Full-Year 2022 financial results.
We announced the upgrade of our powder characterization capabilities at our Tampa (US) site.
We completed the clinical and commercial drug product manufacturing line in Visp (CH).
We announced the initiation of our share buyback program of up to CHF 2 billion.
We announced the acquisition of Synaffix to strengthen our antibody-drug conjugates offering.
We signed a ten-year Virtual Power Purchase Agreement (VPPA) that will provide solar energy equal to Lonza’s electricity needs across Switzerland and the European Union.
We announced an agreement with Vertex to build a dedicated manufacturing facility for Type-1 diabetes (T1D) cell therapies.
We announced the launch of the TheraPRO® CHO media system to improve productivity and quality in therapeutic protein manufacture.
We communicated our Half-Year 2023 financial results.
We launched the Nebula® Absorbance Reader for streamlined endotoxin and pyrogen testing.
We announced the upgrade of our MODA-ES® Module for enhanced electronic batch record execution.
We announced the expansion of the collaboration with a major biopharmaceutical partner for the manufacture of antibody-drug conjugates.
We announced a new filling line for commercial supply of antibody-drug conjugates for a dedicated customer.
We announced the expansion of our collaboration with Vaxcyte to include global commercial manufacturing of pneumococcal conjugate vaccines (PCVs).
At our Capital Markets Day 2023, we announced our new Mid-Term Guidance 2024 – 2028 and confirmed our 2023 Outlook.
